Pieris Tax Provision from 2010 to 2024
| PIRS Stock | USD 11.18 0.21 1.91% |
Tax Provision | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 299 K |
Check Pieris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pieris main balance sheet or income statement drivers, such as Selling General Administrative of 13.5 M, Other Operating Expenses of 46.1 M or Total Operating Expenses of 45.9 M, as well as many exotic indicators such as Price To Sales Ratio of 0.36, Dividend Yield of 0.0 or PTB Ratio of 0.58. Pieris financial statements analysis is a perfect complement when working with Pieris Pharmaceuticals Valuation or Volatility modules.
Pieris | Tax Provision |
Latest Pieris Pharmaceuticals' Tax Provision Growth Pattern
Below is the plot of the Tax Provision of Pieris Pharmaceuticals over the last few years. It is the amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities. Pieris Pharmaceuticals' Tax Provision historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pieris Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Tax Provision | 10 Years Trend |
|
Tax Provision |
| Timeline |
Pieris Tax Provision Regression Statistics
| Arithmetic Mean | 156,013 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 191.63 | |
| Mean Deviation | 166,410 | |
| Median | 164,000 | |
| Standard Deviation | 298,970 | |
| Sample Variance | 89.4B | |
| Range | 1.4M | |
| R-Value | (0.29) | |
| Mean Square Error | 88B | |
| R-Squared | 0.09 | |
| Significance | 0.29 | |
| Slope | (19,594) | |
| Total Sum of Squares | 1.3T |
Pieris Tax Provision History
About Pieris Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Pieris Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Pieris Pharmaceuticals investors use historical funamental indicators, such as Pieris Pharmaceuticals's Tax Provision, to determine how well the company is positioned to perform in the future. Although Pieris Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Pieris Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pieris Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pieris Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pieris Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Tax Provision | 0.00 | 0.00 |
Pair Trading with Pieris Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pieris Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pieris Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Pieris Stock
| 0.52 | MRK | Merck Company Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Pieris Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pieris Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pieris Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pieris Pharmaceuticals to buy it.
The correlation of Pieris Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pieris Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pieris Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pieris Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Pieris Pharmaceuticals Correlation against competitors. For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Pieris Stock analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Pieris Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pieris Pharmaceuticals. If investors know Pieris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pieris Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (21.60) | Revenue Per Share 38.026 | Quarterly Revenue Growth (0.78) | Return On Assets (0.15) | Return On Equity (0.90) |
The market value of Pieris Pharmaceuticals is measured differently than its book value, which is the value of Pieris that is recorded on the company's balance sheet. Investors also form their own opinion of Pieris Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pieris Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pieris Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pieris Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pieris Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pieris Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pieris Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.